keyword
MENU ▼
Read by QxMD icon Read
search

Abraxane

keyword
https://www.readbyqxmd.com/read/29763773/ultrasound-doppler-as-an-imaging-modality-for-selection-of-murine-4t1-breast-tumors-for-combination-radiofrequency-hyperthermia-and-chemotherapy
#1
Martyna Krzykawska-Serda, Jason Chak-Shing Ho, Matthew J Ware, Justin J Law, Jared M Newton, Lam Nguyen, Mahdi Agha, Steven A Curley, Stuart J Corr
Noninvasive radiofrequency-induced (RF) hyperthermia has been shown to increase the perfusion of chemotherapeutics and nanomaterials through cancer tissue in ectopic and orthotopic murine tumor models. Additionally, mild hyperthermia (37°C-45°C) has previously shown a synergistic anticancer effect when used with standard-of-care chemotherapeutics such as gemcitabine and Abraxane. However, RF hyperthermia treatment schedules remain unoptimized, and the mechanisms of action of hyperthermia and how they change when treating various tumor phenotypes are poorly understood...
May 11, 2018: Translational Oncology
https://www.readbyqxmd.com/read/29755355/bio-inspired-protein-based-nanoformulations-for-cancer-theranostics
#2
REVIEW
Yi Gou, Dandan Miao, Min Zhou, Lijuan Wang, Hongyu Zhou, Gaoxing Su
Over the past decade, more interests have been aroused in engineering protein-based nanoformulations for cancer treatment. This excitement originates from the success of FDA approved Abraxane (Albumin-based paclitaxel nanoparticles) in 2005. The new generation of biocompatible endogenous protein-based nanoformulations is currently constructed through delivering cancer therapeutic and diagnostic agents simultaneously, as named potential theranostics. Protein nanoformulations are commonly incorporated with dyes, contrast agents, drug payloads or inorganic nanoclusters, serving as imaging-guided combinatorial cancer therapeutics...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29747311/-study-of-bioequiavailability-of-paclitaxel-for-injection-albumin-bound-and-abraxane-and-the-efficacy-of-extension-treatments-in-patients-with-metastatic-breast-cancer
#3
L Bian, C Z Geng, Q C Ouyang, X C Hu, Y Y Peng, J Y Xiao, M X Wang, N Yang, J Yuan, Y M Wang, Z F Jiang
Objective: To compare the bioequiavailability of paclitaxel for injection (albumin bound) (PAB) and reference listed drug abraxane in the patients with metastatic breast cancer, and to investigate the safety and efficacy in the extension treatments of PAB. Methods: This study was random, two cycles, self-crossover control study in the bioequiavailability stage. PAB was the investigational drug T and Abraxane was the reference drug R. Patients were randomly assigned to two cycles therapy of either R→T or T→R(260 mg/m(2)/21d)...
April 24, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29648446/evans-blue-derivative-functionalized-gold-nanorods-for-photothermal-therapy-enhanced-tumor-chemotherapy
#4
Xiangyu Wang, Shi Gao, Zainen Qin, Rui Tian, Guohao Wang, Xianzhong Zhang, Lei Zhu, Xiaoyuan Chen
Chemotherapy is a standard care for cancer management, but the lack of tumor targeting and high dose-induced side effects still limit its utility in patients. Here, we report a chemotherapy combined with photothermal therapy (PTT) for enhanced cancer ablation by functionalization of gold nanorods (GNR) with a novel small molecule named truncated Evans Blue (tEB). Based on the high binding affinity of tEB with albumin, an Abraxane-like nanodrug, human serum albumin/hydroxycamptothecin (HSA/HCPT), was further complexed with GNR-tEB...
April 12, 2018: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/29625422/paclitaxel-and-di-fluorinated-curcumin-loaded-in-albumin-nanoparticles-for-targeted-synergistic-combination-therapy-of-ovarian-and-cervical-cancers
#5
Kaustubh A Gawde, Samaresh Sau, Katyayani Tatiparti, Sushil K Kashaw, Mohammad Mehrmohammadi, Asfar S Azmi, Arun K Iyer
Paclitaxel (PTX) encapsulated in albumin (Abraxane® ) is an FDA approved frontline nano-formulation for treating advance metastatic pancreatic, lung and breast cancers. Currently in clinic, Abraxane® is being used as a one of the components of combination therapy regimens. On the other hand, difluorinated curcumin (CDF) is a novel and potent synthetic curcumin analogue that is being evaluated for several malignancies including pancreatic, liver, ovarian and breast cancers. To improve the bioavailability and targeting ability of hydrophobic PTX and CDF, we have encapsulated them in folic acid decorated bovine serum albumin nanoparticles, namely FA-BSA-PTX and FA-BSA-CDF, respectively...
March 28, 2018: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/29570231/a-comparative-in-vivo-study-of-albumin-coated-paclitaxel-nanocrystals-and-abraxane
#6
Joonyoung Park, Ji Eun Park, Victoria E Hedrick, Karl V Wood, Connie Bonham, Wooin Lee, Yoon Yeo
Nanoparticulate drug carriers exploit the enhanced permeability of tumor vasculature to achieve selective delivery of chemotherapeutic drugs. For this purpose, nanoparticles (NPs) need to circulate with a long half-life, enter tumors via the permeable vasculature and stay in tumors via favorable interactions with tumor cells. To fulfill these requirements, albumin-coated nanocrystal formulation of paclitaxel (PTX), Cim-F-alb, featuring high drug loading content, physical stability in serum, and surface-bound albumin in its native conformation is prepared...
March 23, 2018: Small
https://www.readbyqxmd.com/read/29564179/the-nab-paclitaxel-gemcitabine-regimen-for-patients-with-refractory-advanced-pancreatic-adenocarcinoma
#7
Sofia Palacio, Peter J Hosein, Isildinha Reis, Ikechukwu I Akunyili, Vinicius Ernani, Terri Pollack, Jessica Macintyre, Maria H Restrepo, Jaime R Merchan, Caio M Rocha Lima
The phase III MPACT trial for metastatic pancreatic cancer (PC) showed improved overall survival (OS), progression free survival (PFS) and response rates (RRs) for first-line nab -paclitaxel (Abraxane) and gemcitabine (the AG combination) compared to gemcitabine monotherapy. The safety and efficacy of the AG combination has not been systematically studied as second-line therapy or beyond for metastatic PC. We conducted an IRB-approved retrospective analysis of all patients diagnosed between September 2010 and August 2014 with advanced refractory PC that received combination treatment with AG at our institution...
February 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29555439/current-development-in-the-formulations-of-non-injection-administration-of-paclitaxel
#8
REVIEW
Xiyou Du, Abdur Rauf Khan, Manfei Fu, JianboJi, Aihua Yu, Guangxi Zhai
Paclitaxel (PTX) belongs to a class of taxane anti-tumor drug used for the clinic treatment of breast cancer, ovarian cancer, non-small-cell lung cancer, and so on. PTX has poor water solubility and oral bioavailability. It is generally administered via intravenous (i.v.) infusion. Traditional PTX injectable preparations contain Cremophor-EL and ethanol to improve its solubility, which would result in adverse reactions like severe hypersensitivity, neutropenia, etc. Adverse reactions can be reduced only by complicated pretreatment with glucocorticoid and antihistamines drugs and followed by PTX slow infusion for three hours, which has brought significant inconvenience to the patients...
March 16, 2018: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29508606/self-templated-green-synthetic-size-controlled-protein-nanoassembly-as-a-robust-nanoplatform-for-biomedical-application
#9
Ya Wen, Haiqing Dong, Kun Wang, Yan Li, Yongyong Li
Despite inherent advantages over their synthetic polymer-based counterparts, protein nanoparticles remain unsatisfactory in fabrication owing to their low size control, usage of toxic cross-linkers, or organic solvents. This partially contributes to the marginal benefits of Abraxane in clinics. Herein, a green-synthetic, size-controlled approach was developed to generate stable albumin nanoparticles. Physically packed ovalbumin nanoclusters were temporally formed in heat, which was then used as the template to form protein nanoparticles chemically stabilized by the intermolecular disulfide network...
April 11, 2018: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/29483955/recombinant-nanocomposites-by-the-clinical-drugs-of-abraxane-%C3%A2-and-herceptin-%C3%A2-as-sequentially-dual-targeting-therapeutics-for-breast-cancer
#10
Shuang Ding, Jian Xiong, Dan Lei, Xiao-Li Zhu, Hai-Jun Zhang
Breast cancer greatly threatens the health of women all over the word despite of several effective drugs. Targeted therapy for breast cancer is limited to human epidermal growth factor receptor 2 (HER2). Herceptin® , monoclonal antibody against HER2, is now widely used in HER2(+) breast cancer. Abraxane® , the current gold standard for paclitaxel (PTX) delivery, has shown superiority in breast cancer based on nanoparticle albumin bound technology. Despite these advances, further novel targeted therapy with more improved anti-tumor efficacy for breast cancer is still urgently needed...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29434168/compatibility-and-stability-of-nab-paclitaxel-in-combination-with-other-drugs
#11
Naomi Mizuta, Tsutomu Nakagawa, Kazuhiro Yamamoto, Tatsuya Nishioka, Manabu Kume, Hiroo Makimoto, Ikuko Yano, Hironobu Minami, Midori Hirai
Albumin-bound paclitaxel (Abraxane®, nab-paclitaxel) is not recommended to be administered concurrently or sequentially with other drugs due to concern for instability. The need to administer drugs separately increases infusion time. We evaluated the compatibility and stability of solutions containing nab-paclitaxel and other drugs, including gemcitabine hydrochloride, carboplatin, dexamethasone sodium phosphate, granisetron hydrochloride, and palonosetron hydrochloride. We visually examined changes in appearance, pH, and concentration of the mixed solutions of nab-paclitaxel and other drugs for up to 24 h...
July 20, 2017: Kobe Journal of Medical Sciences
https://www.readbyqxmd.com/read/29362902/a-phase-i-dose-escalation-trial-of-nab-paclitaxel-and-fixed-dose-radiation-in-patients-with-unresectable-or-borderline-resectable-pancreatic-cancer
#12
Jacob E Shabason, Jerry Chen, Smith Apisarnthanarax, Nevena Damjanov, Bruce Giantonio, Arturo Loaiza-Bonilla, Peter J O'Dwyer, Mark O'Hara, Kim A Reiss, Ursina Teitelbaum, Paul Wissel, Jeffrey A Drebin, Charles Vollmer, Michael Kochman, Rosemarie Mick, Norge Vergara, Nirag Jhala, Abigail Doucette, John N Lukens, John P Plastaras, James M Metz, Edgar Ben-Josef
PURPOSE: Patients with locally advanced pancreatic cancer typically have poor outcomes, with a median survival of approximately 16 months. Novel methods to improve outcomes are needed. Nab-paclitaxel (Abraxane) has shown efficacy in pancreatic cancer and is FDA-approved for metastatic disease in combination with gemcitabine. Nab-paclitaxel is also a promising radiosensitizer based on laboratory studies, but it has never been clinically tested with definitive radiotherapy for locally advanced pancreatic carcinoma...
March 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29328489/antibody-nanoparticle-conjugate-constructed-with-trastuzumab-and-nanoparticle-albumin-bound-paclitaxel-for-targeted-therapy-of-human-epidermal-growth-factor-receptor-2-positive-gastric-cancer
#13
Jian Xiong, Shuhua Han, Shuang Ding, Jingchao He, Haijun Zhang
Gastric cancer (GC) is the most lethal malignancy in the digestive system. This study investigated an antibody-nanoparticle conjugate (ANC) constructed with trastuzumab (Herceptin®) and nanoparticle albumin-bound paclitaxel (nab-paclitaxel, Abraxane®) (trastuzumab/nab‑paclitaxel) as a novel strategy of targeted therapy for human epidermal growth factor receptor 2 (HER2) positive GC. The ANC was fabricated with trastuzumab and nab‑paclitaxel by a 'one-step' synthesis using EDC/NHS. In vitro antitumor efficacy was evaluated by cell viability, apoptosis rate and cell cycle of HER2-positive GC NCI‑N87 cells and compared with paclitaxel (Taxol®), nab‑paclitaxel and trastuzumab/nab‑paclitaxel...
March 2018: Oncology Reports
https://www.readbyqxmd.com/read/29327055/comparing-neoadjuvant-nab-paclitaxel-vs-paclitaxel-both-followed-by-anthracycline-regimens-in-women-with-erbb2-her2-negative-breast-cancer-the-evaluating-treatment-with-neoadjuvant-abraxane-etna-trial-a-randomized-phase-3-clinical-trial
#14
Luca Gianni, Mauro Mansutti, Antonio Anton, Lourdes Calvo, Giancarlo Bisagni, Begoña Bermejo, Vladimir Semiglazov, Marc Thill, Jose Ignacio Chacon, Arlene Chan, Serafin Morales, Isabel Alvarez, Arrate Plazaola, Milvia Zambetti, Andrew D Redfern, Christian Dittrich, Rebecca Alexandra Dent, Domenico Magazzù, Raffaella De Fato, Pinuccia Valagussa, Ignacio Tusquets
Importance: Studies of neoadjuvant chemotherapy regimens using anthracyclines followed by taxanes have reported a doubling of pathological complete remission (pCR) rates compared with anthracycline-based regimens alone. A reverse sequence did not reduce activity. Nab-paclitaxel is an albumin-bound nanoparticle of paclitaxel that allows for safe infusion without premedication, and its use led to a significantly higher rate of pCR in the GeparSepto trial. Objective: To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting...
March 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29325755/amphotericin-b-albumin-conjugates-synthesis-toxicity-and-anti-fungal-activity
#15
Sneha Gurudevan, Arul Prakash Francis, A Jayakrishnan
Amphotericin B (AmB), a hydrophobic drug with negligible aqueous solubility was conjugated to bovine serum albumin (BSA) via amide bond coupling to give 6 to 8 wt% drug payload. The resulting conjugate was characterized using SDS-PAGE and UV-visible, FTIR and CD spectroscopy. The conjugate was water-soluble to the extent of 150 mg/ml, was non-toxic to HEK 293 T cells at a concentration of 500 μg/ml (equivalent to ~30 μg AmB) and showed hemolysis of <5% at 200 μg/ml (equivalent to ~12 μg AmB) against human erythrocytes in vitro...
March 30, 2018: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29221990/molecular-and-cellular-mechanisms-of-chemoresistance-in-pancreatic-cancer
#16
REVIEW
Aleksandra Adamska, Omar Elaskalani, Aikaterini Emmanouilidi, Minkyoung Kim, Norbaini Binti Abdol Razak, Pat Metharom, Marco Falasca
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant cancers, and current therapies targeting cancer-associated molecular pathways have not given satisfactory results, owing in part to rapid upregulation of alternative compensatory pathways. Most of the available treatments are palliative, focussing on improving the quality of life. At present, available options are surgery, embolization, radiation, chemotherapy, immunotherapy and use of other more targeted drugs. In this review, we describe the cellular and molecular effects of current chemotherapy drugs such as gemcitabine, FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and ABRAXANE (nab-Paclitaxel), which have shown a survival benefit, although modest, for pancreatic cancer patients...
November 22, 2017: Advances in Biological Regulation
https://www.readbyqxmd.com/read/29203865/albumin-vaccine-nanocomplexes-that-assemble-in-vivo-for-combination-cancer-immunotherapy
#17
Guizhi Zhu, Geoffrey M Lynn, Orit Jacobson, Kai Chen, Yi Liu, Huimin Zhang, Ying Ma, Fuwu Zhang, Rui Tian, Qianqian Ni, Siyuan Cheng, Zhantong Wang, Nan Lu, Bryant C Yung, Zhe Wang, Lixin Lang, Xiao Fu, Albert Jin, Ido D Weiss, Harshad Vishwasrao, Gang Niu, Hari Shroff, Dennis M Klinman, Robert A Seder, Xiaoyuan Chen
Subunit vaccines have been investigated in over 1000 clinical trials of cancer immunotherapy, but have shown limited efficacy. Nanovaccines may improve efficacy but have rarely been clinically translated. By conjugating molecular vaccines with Evans blue (EB) into albumin-binding vaccines (AlbiVax), here we develop clinically promising albumin/AlbiVax nanocomplexes that self-assemble in vivo from AlbiVax and endogenous albumin for efficient vaccine delivery and potent cancer immunotherapy. PET pharmacoimaging, super-resolution microscopies, and flow cytometry reveal almost 100-fold more efficient co-delivery of CpG and antigens (Ags) to lymph nodes (LNs) by albumin/AlbiVax than benchmark incomplete Freund's adjuvant (IFA)...
December 5, 2017: Nature Communications
https://www.readbyqxmd.com/read/29170482/a-new-approach-to-deliver-anti-cancer-nanodrugs-with-reduced-off-target-toxicities-and-improved-efficiency-by-temporarily-blunting-the-reticuloendothelial-system-with-intralipid
#18
Li Liu, Qing Ye, Maggie Lu, Shih-Ta Chen, Hsiang-Wen Tseng, Ya-Chin Lo, Chien Ho
We have developed a new strategy to temporarily blunt the reticuloendothelial system uptake of nanodrugs, a major challenge for nanodrug delivery and causing off-target toxicities, using an FDA approved nutrition supplement, Intralipid. We have tested our methodology in rats using an experimental platinum-containing anti-cancer nanodrug and three FDA approved nanodrugs, Abraxane, Marqibo, and Onivyde, to determine their toxicities in liver, spleen, and kidney, with and without the addition of Intralipid. Our method illustrates its potentials to deliver nanodrugs with an increase in the bioavailability and a decrease in toxicities...
November 23, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29139187/pharmacokinetics-and-safety-of-paclitaxel-delivery-into-porcine-airway-walls-by-a-new-endobronchial-drug-delivery-catheter
#19
Hisashi Tsukada, Plamena Entcheva-Dimitrov, Armin Ernst, Samaan Rafeq, John H Keating, Kirk P Seward, Lonny Yarmus
BACKGROUND AND OBJECTIVE: Intratumoral administration of chemotherapeutic agents is a treatment modality that has proven efficacious in reducing the recurrence of tumours and increases specificity of treatment while minimizing systemic side effects. Direct intratumoral injection of malignant airway obstruction has potential therapeutic benefits but tissue drug concentrations and side-effect profiles are poorly understood. METHODS: Bronchial wall injection of generic paclitaxel (PTX) (102 injections of 0...
April 2018: Respirology: Official Journal of the Asian Pacific Society of Respirology
https://www.readbyqxmd.com/read/29111494/macrophages-as-a-potential-tumor-microenvironment-target-for-noninvasive-imaging-of-early-response-to-anticancer-therapy
#20
Qizhen Cao, Xinrui Yan, Kai Chen, Qian Huang, Marites P Melancon, Gabriel Lopez, Zhen Cheng, Chun Li
As a result of therapy-induced apoptosis, peripheral blood monocytes are recruited to tumors, where they become tumor-associated macrophages (TAMs). To date, few studies have investigated noninvasive molecular imaging for assessment of macrophage infiltration in response to therapy-induced apoptosis. Here, noninvasive assessment of changes in tumor accumulation of TAMs was proposed as a new way to measure early tumor response to anticancer therapy. Three different nanoparticles, QD710-Dendron quantum dots (QD710-D), Ferumoxytol, and PG-Gd-NIR813, were used for near-infrared fluorescence imaging, T2-weighted magnetic resonance imaging, and dual optical/T1-weighted MR imaging, respectively, in the MDA-MB-435 tumor model...
January 2018: Biomaterials
keyword
keyword
115581
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"